Article in GigaScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Jing WangDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA.ORCID 0000-0003-2775-9001
Hua-Chang ChenDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA.ORCID 0000-0003-0497-2483
Scott W HiebertDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37205, USA.ORCID 0000-0001-5621-1454
Quanhu ShengDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA.ORCID 0000-0001-8951-9295
William P TanseyDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37205, USA.ORCID 0000-0002-3900-0978
Yu ShyrDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA.ORCID 0000-0003-2086-9670
Qi LiuDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA.ORCID 0000-0001-8892-7078
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Role of Iron and B-Catenin Activation in Gastric CarcinogenesisP01CA116087 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Maria Blanca Piazuelo · 2009 to 2026
$27.5M
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEPHEN W. FESIK · 2019 to 2026
$19.6M
Roles for Supermeres in CRC ProgressionP01CA229123 · NCI · VANDERBILT UNIVERSITY · PI Alissa M Weaver · 2020 to 2026
$12.9M
Project 3 - Differential contribution of thymic APCs to central tolerance during the perinatal to adult transitionP01AI139449 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RICHIE, ELLEN R · 2020 to 2024
$12.0M
Shaping the Microenvironment by DPEP1 Facilitates Adenoma ProgressionU54CA274367 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bhuminder Singh · 2022 to 2026
$9.7M
Facilitated recruitment of MYC to chromatin by interaction with WDR5R01CA200709 · NCI · VANDERBILT UNIVERSITY · PI TANSEY, WILLIAM PATRICK · 2016 to 2025
$3.9M
The MYC-SWI/SNF connection in rhabdoid tumorsR01CA247833 · NCI · VANDERBILT UNIVERSITY · PI TANSEY, WILLIAM PATRICK · 2020 to 2024
Nascent RNA sequencing tracks primary transcriptional events, making it crucial for studying the immediate regulatory changes of genes and enhancers in response to both endogenous and exogenous stimuli. NRSA is a widely used tool for analyzing nascent transcriptomic data, enabling quantification of transcriptional changes at proximal promoters and gene bodies, estimation of pausing indices, identifying active enhancers, and establishing enhancer-target gene relationships. To improve its functionality and broaden its applicability to diverse organisms and complex study designs, we have developed an enhanced version, eNRSA. Key advancements include adaptive selection of major transcripts, support for any organism with known gene structures, compatibility with complex study designs, and identification of alternative transcription start and termination sites, as well as transcription readthrough events. Additionally, eNRSA achieves a ∼20-fold increase in analysis speed while significantly reducing memory usage. These enhancements make eNRSA a faster, more versatile, and more powerful tool for nascent transcriptome analysis. eNRSA is freely available at https://bioinfo.vanderbilt.edu/eNRSA/.
Indexed as
Gene Expression ProfilingSoftwareTranscriptomeAnimalsComputational BiologyHumansPromoter Regions, GeneticSequence Analysis, RNAadaptive major transcriptalternative transcription start site (ATSS)alternative transcription termination site (ATTS)nascent transcriptome analysistranscription readthrough
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
eNRSA: a faster and more powerful approach for nascent transcriptome analysis. · full record | OpenQuestion